Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines

Abstract

AbstractThe large‐scale production of clinical‐grade lentiviral vectors (LVs) for gene therapy applications is a remaining challenge. The use of adherent cell lines and methods like transient transfection are cost‐intensive and hamper process scalability as well as reproducibility. This study describes the use of two suspension‐adapted stable packaging cell lines, called GPRGs and GPRTGs, for the development of a scalable and serum‐free LV production process. Both stable packaging cell lines are based on an inducible Tet‐off system, thus requiring doxycycline removal for initiation of the virus production. Therefore, we compared different methods for doxycycline removal and inoculated three independent 5 L bioreactors using a scalable induction method by dilution, an acoustic cell washer and manual centrifugation. The bioreactors were inoculated with a stable producer cell line encoding for a LV carrying a clinically relevant gene. LV production was performed in perfusion mode using a cell retention device based on acoustic wave separation. Comparable cell‐specific productivities were obtained with all three methods and cumulative functional yields up to 6.36 × 1011 transducing units per bioreactor were generated in a 234‐h long process, demonstrating the usability of stable Tet‐off cell lines for an easily scalable suspension process. Remarkably, cell viabilities >90% were maintained at high cell densities without compromising productivity throughout the whole process, allowing to further extend the process time. Given its low effects of toxicity during virus production, the presented cell lines are excellent candidates to develop a fully continuous LV production process to overcome the existing bottlenecks in LV manufacturing.